# Amkor Technology Inc. (AMKR) — Financial Analysis

**Exchange:** NASDAQ  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-28  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/AMKR/thesis · /stocks/AMKR/memo

## Financial Snapshot

---
ticker: AMKR
step: 04
title: Financial Quality & Adversarial Sweep
source: coverage-next-full
date: 2026-05-28
---

### Step 04 — Financial Quality & Adversarial Sweep

#### Key Findings

**Net assessment: net positive — financial quality is high; adversarial sweep finds no material red flags.** AMKR's financial statements demonstrate **strong cash conversion** (CFO consistently >2× net income), **conservative leverage** (~$700M net cash, LT debt $1.3B vs equity $4.5B), and **no material restatements** in the 8-year XBRL window. The Adversarial Sweep finds **no active short reports, no SEC enforcement actions, no material litigation beyond ordinary course, and no governance controversies**. The most notable accounting-quality issue is the **Nanium insolvency receipt ($32.4M FY2025 benefit)** — a one-time SG&A reduction that should be normalized out for run-rate analysis [S1].

#### Implications for Thesis and Valuation

1. **No accounting trickery** — earnings quality supports use of reported numbers (with minor normalizations) for DCF and multiples
2. **Strong cash position** = limited refinancing risk; flexibility to absorb capex cycle without dilution
3. **One-time items in FY2025** (Nanium receipt $32M, machinery gain in GP, debt retirement loss) should be normalized — see assumption register
4. **Recurring high cash conversion** is structurally driven by heavy non-cash D&A on PPE base; this is real, not a smoothing artifact

#### Objective

Stress-test AMKR's financial statements for quality issues, identify any adversarial signals (short reports, lawsuits, restatements), and document one-time items requiring normalization.

#### Narrative Analysis

##### Financial quality dimensions

**1. Revenue recognition: Clean.** AMKR recognizes revenue point-in-time upon transfer of finished packaged goods to the customer. Customer-consigned wafers do NOT inflate revenue (AMKR doesn't take title to silicon). Contract liabilities for customer advance payments are disclosed and normal for a services business. No channel-stuffing risk because the business is direct-to-customer (no distribution channels).

**2. Cost capitalization vs. expense: Conservative.**
- R&D is expensed as incurred ($167M in FY2025) [S2]
- Capex is capitalized normally (12-15% of revenue per year)
- No aggressive software/IP capitalization
- Depreciation matches D&A schedules — no acceleration to depress current earnings or smooth into future

**3. Cash conversion: Excellent.**

| FY | CFO ($M) | Net Income ($M) | CFO / NI Ratio |
|---:|---------:|----------------:|---------------:|
| 2018 | 663 | 127 | 5.2× |
| 2019 | 564 | 121 | 4.7× |
| 2020 | 770 | 338 | 2.3× |
| 2021 | 1,121 | 643 | 1.7× |
| 2022 | 1,099 | 766 | 1.4× |
| 2023 | 1,270 | 360 | 3.5× |
| 2024 | 1,089 | 354 | 3.1× |
| 2025 | 1,096 | 374 | 2.9× |

The CFO/NI ratio is structurally high (>2× through cycle) because:
- Heavy non-cash D&A on $4-5B PPE base (~$600M+ annual D&A)
- Capex above D&A reflects growth, not maintenance
- Working capital is reasonably stable (inventory turns 4-5×)

**4. Working capital quality: Stable.**

| Period | Inventory ($M) | AR Days (approx) | AP Days (approx) |
|--------|---------------:|-----------------:|-----------------:|
| FY2022 | 630 | 65 | 80 |
| FY2023 | 393 | 62 | 75 |
| FY2024 | 311 | 60 | 72 |
| FY2025 | 438 | 65 | 78 |

Inventory built up in FY2022 (cyclical peak) and worked down in FY2023-2024 — normal pattern. FY2025 inventory rebuild reflects revenue recovery. No DSO (days sales outstanding) creep.

**5. Balance sheet quality: Strong.**

| Period | Net Cash ($M) | Equity ($M) | D/E |
|--------|-------------:|-----------:|----:|
| 2019 YE | -411 | 1,964 | 21% |
| 2022 YE | -130 | 3,669 | 4% |
| 2024 YE | 211 | 4,150 | (5%) net cash |
| 2025 YE | 708 | 4,471 | (16%) net cash |
| 2026 Q1 | -136 | 4,534 | 3% (drew down for capex) |

Steady deleveraging through the cycle. Q1 2026 saw a temporary net debt position due to heavy capex; expected to swing back to net cash by Q2-Q3 2026 per management commentary.

**6. Off-balance-sheet exposures:**
- Operating leases: ~$100-150M (not large)
- Customer commitments: AMKR typically has 6-12 month customer commitments providing forecast visibility but no guarantees
- No special purpose entities, no material derivatives beyond FX hedging
- No JVs of material size

**7. Tax quality:**

ETR FY2025: 15.4% — below US 21% statutory due to:
- Korea reduced rates (conditional tax holiday)
- Singapore reduced rates (conditional)
- Vietnam reduced rates (conditional)
- Discrete tax benefits recognized in FY2025

Risks:
- Tax holiday expirations could lift ETR over time
- Korea Pillar 2 (OECD global minimum tax) implementation could affect Korean operations
- US OBBBA tax changes (July 2025) generally favorable (CHIPS ITC raised to 35%)

**No history of contentious tax positions, deferred tax asset write-downs of consequence, or APB 23 issues.**

##### Adversarial Research Sweep

A targeted search for negative signals across multiple dimensions:

**1. Short reports / activist short campaigns:**
- **None identified.** No Hindenburg, Muddy Waters, Citron, or other notable short-seller campaigns active or recently closed against AMKR (per web search synthesis, 2026-05-28). Hindenburg shut down in early 2025 anyway.
- Short interest data not separately pulled but historically low for AMKR (mid-single digits % of float).

**2. SEC enforcement / regulatory actions:**
- **None identified.** No material SEC settlements, formal investigations, or enforcement actions in the past 5 years.
- Standard 10-K Item 3 (Legal Proceedings) language indicates only ordinary-course IP licensing and commercial disputes.

**3. Restatements / financial reporting issues:**
- **None identified** in 5-year window. XBRL data shows consistent prior-period values across filings (i.e., no reclassifications or restatements beyond ASC 606 transition in 2018).

**4. Whistleblower / DOJ investigations:**
- **None identified.**

**5. Class action lawsuits:**
- Standard securities class action checks: no active material cases identified in recent years.
- AMKR has historical IP-related litigation with Tessera (resolved 2018) and others — all closed.

**6. Material customer disputes:**
- Nanium subsidiary insolvency (Portugal-based) — this is a *recovery* (AMKR received $32.4M back from the insolvency proceedings in FY2025) [S2]. Nanium was acquired and the European recession/restructuring led to its later insolvency; AMKR has now received some recovery.

**7. Governance controversies:**
- Kim family 49.4% control is structural, not a controversy (well-disclosed, long-standing)
- CEO transition (Rutten → Engel) appears orderly and well-planned, not crisis-driven
- No proxy advisor (ISS, Glass Lewis) issues at recent annual meetings
- Compensation packages broadly aligned with semis-peer norms

**8. Auditor concerns:**
- PricewaterhouseCoopers serves as auditor (long-tenured)
- No critical audit matter (CAM) of unusual concern in FY2025 10-K
- No going-concern issues or material weakness disclosures

**9. Geopolitical / export control issues:**
- Standard semi industry exposure to US-China export controls
- No specific OFAC sanctions or Entity List actions against AMKR
- Continued ability to operate in China (no forced divestiture)

##### One-time items requiring normalization

For run-rate analysis in /complete-coverage, the following FY2025 items should be normalized:

| Item | $M Impact | Direction | Normalization |
|------|----------:|-----------|----------------|
| Nanium insolvency receipt | +$32.4M | Boosted SG&A negative (reduced expense) | Exclude from run-rate SG&A |
| Gain on sale of machinery (in GP) | est ~$10-30M | Boosted GP | Should be excluded from underlying GM% |
| Loss on debt retirement | -$1.8M | Reduced earnings | Exclude (non-operating) |
| Vietnam start-up costs (in SG&A) | ~$0 FY2025 vs $16M FY2024 | – | FY2024 was elevated; FY2025 was normalized |
| FX (gain)/loss net | -$10.8M FY2025 | Reduced earnings | Cyclical; trend through cycle |

After normalization, "underlying" FY2025 operating income is ~$430-450M (vs. reported $467M) — a more conservative starting point.

##### Adversarial Sweep — Key Concerns That Are NOT Red Flags (but worth flagging for transparency)

1. **Q4 spike volatility:** FY2023 Q4 NI = $400M and FY2024 Q4 NI = $517M look unusual vs. adjacent quarters, but these reflect **tax-related credits and discrete items**, not operational manipulation. They are visible in the 10-K Item 8 tax footnote (not extracted here in detail but referenced in MD&A) [S2].

2. **Kim family related-party transactions:** Standard pre-approval policies via Audit Committee. No material RPTs of concern disclosed in 2026 DEF 14A.

3. **Korea operations exposure:** Concentrated production in Korea creates Korea-political-risk, but Korea is a stable US ally; this is geographic-diversity diligence, not a red flag.

4. **Heavy customer concentration:** Apple 30% + Qualcomm 11% — this is widely understood and modeled by analysts. Not hidden; not a quality issue.

#### Evidence and Sources

##### Cash flow quality validation

FY2025 cash flow statement reconciliation [S2]:
- Net Income: $374M
- Add: D&A ~$610M
- Add: SBC ~$50M (estimate)
- Working capital change: ~+$60M
- Other: ~$0M
- **CFO: ~$1,094M** (reported $1,096M ✓)

D&A is the largest non-cash add-back, reflecting AMKR's capital-intensive PPE base. SBC is modest (~0.7% of revenue) — appropriate for an industrial-services business.

##### Debt structure (FY2025 YE)

| Item | Amount ($M) | Notes |
|------|------------:|-------|
| Cash & equivalents | 1,378 | |
| ST investments | 613 | |
| Total liquid assets | 1,991 | |
| ST debt (incl. current LTD) | ~150 (est) | Annual maturities |
| LT debt non-current | 1,283 | |
| **Net debt / (net cash)** | **(708)** | Net cash position |

AMKR's debt is largely senior notes maturing 2027-2032 — staggered maturity ladder reduces refinancing risk.

#### Assumption Register Updates

| ID | Step | Assumption | Type | Value | Unit | Source |
|----|------|------------|------|-------|------|--------|
| A027 | 04 | Through-cycle CFO/NI ratio | Fact | ~2.5-3× | – | XBRL 8-year |
| A028 | 04 | FY2025 Nanium one-time benefit | Fact | $32.4M | $M (SG&A reduction) | 10-K MD&A |
| A029 | 04 | No active short reports | Fact | None identified | – | Web search 2026-05-28 |
| A030 | 04 | No material restatements (5-yr) | Fact | Confirmed | – | XBRL consistency |
| A031 | 04 | Normalized FY2025 operating income | Estimate | ~$435M | $M | After Nanium/gain normalization |
| A032 | 04 | Audit firm | Fact | PwC | – | 10-K Item 14 |

#### Tables and Calculations

##### Earnings quality scorecard

| Dimension | Score | Comment |
|-----------|-------|---------|
| Revenue recognition | A | Point-in-time, simple, no channel risk |
| Cost capitalization | A | Conservative; R&D expensed |
| Cash conversion | A | CFO/NI > 2× consistently |
| Working capital | B+ | Stable; cycle-driven swings |
| Balance sheet strength | A- | Net cash; staggered debt |
| Tax quality | B+ | Reduced rates risk but disclosed |
| Off-balance-sheet | A | Minimal exposures |
| One-time items | B | FY2025 has modest one-time benefits to normalize |
| Audit / SOX | A | PwC; no material weaknesses |
| **Overall** | **A-** | High-quality, normalize for FY2025 one-times |

##### Adversarial sweep scorecard

| Risk Vector | Status | Notes |
|-------------|--------|-------|
| Short reports | Clear | None found |
| SEC actions | Clear | None |
| Restatements | Clear | None in 5-yr window |
| DOJ / FBI | Clear | None |
| Class actions | Clear | Standard ordinary course only |
| Customer disputes | Minor | Nanium insolvency settled with recovery |
| Auditor concerns | Clear | PwC; no CAM concerns |
| Governance | Minor | Kim family control is structural; not a flag |

**Overall adversarial sweep: PASS** — no material red flags.

#### Open Questions and Data Gaps

1. **Detailed customer revenue beyond Apple/Qualcomm** — undisclosed; can't assess "next-tier" concentration
2. **Geographic revenue (customer billing location)** — limited disclosure
3. **Vietnam ramp profitability detail** — embedded in totals
4. **AI-specific revenue $** — not disclosed
5. **Form 4 individual transactions** — pattern-based aggregation only

#### Next-Step Dependencies

- Step 06 (Balance Sheet & Dilution) will deepen debt structure, maturities, and per-share economics
- Step 07 (Capital Allocation) will assess the historical capital allocation record
- Step 13 (Forecast — in /complete-coverage) should use normalized FY2025 operating income (~$435M) as the base, not reported $467M

#### Source Index

| Source Tag | Document or URL | Section | Date | Notes |
|------------|----------------|---------|------|-------|
| [S1] | AMKR FY2025 10-K Item 7 MD&A | Other Income/Expense + Nanium discussion | 2026-02-20 | https://www.sec.gov/Archives/edgar/data/1047127/000104712726000014/amkr-20251231.htm |
| [S2] | AMKR FY2025 10-K Consolidated Financials + Item 8 Notes | Income statement, balance sheet, cash flow | 2026-02-20 | local: `AMKR_financials/sec_filings/10K_FY2025_summary.md` |
| [S3] | XBRL companyfacts CIK 0001047127 | Multi-year financials | 2026-05-28 | local: `AMKR_financials/xbrl/xbrl_summary.md` |
| [S4] | Web search adversarial sweep (Hindenburg / SEC / DOJ / class action) | – | 2026-05-28 | Confirmed no material findings |
| [S5] | AMKR 2026 DEF 14A | Audit Committee + Related Party section | 2026-04-02 | local: `AMKR_financials/proxy/governance_and_compensation.md` |

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/AMKR/fundamental

## Navigation

- Overview: /stocks/AMKR
- Financials (this page): /stocks/AMKR/financials
- Thesis: /stocks/AMKR/thesis
- Investment Memo: /stocks/AMKR/memo
- Coverage universe: /stocks